BioCentury
ARTICLE | Finance

Valuing Intarcia

How Intarcia's valuation, coffers swelled as the diabetes play stayed private

May 4, 2015 7:00 AM UTC

Intarcia Therapeutics Inc.'s new royalty investors are betting the biotech can more than triple its current $1.75 billion valuation in the next four years. The company already has done it once, roughly tripling its value from $635 million in 2012.

Last week, Intarcia received $225 million from undisclosed investors in exchange for a 1.5% royalty on future global sales of ITCA 650, which is in Phase III testing to treat Type II diabetes. The once-yearly product provides continuous subcutaneous delivery of the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide via the implantable Duros osmotic minipump. Intarcia expects to submit an NDA to FDA in 1H16 and hopes to launch ITCA 650 in 2017. ...